Revenue
2016
2017
2018
2019
2022
2023
2024
2025
Monopar Therapeutics (MNPR)
Price$117.56Cached quote
Net income
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | $0 | $0 | $0 | $0 |
| Research & development | $9.9M | $13.0M | $5.6M | $7.6M | $6.5M | $4.1M | $2.0M | $1.8M | $935,319 | $280,355 |
| Operating expenses | $16.7M | $16.2M | $8.8M | $10.5M | $9.1M | $6.5M | $4.3M | $3.3M | $16.6M | $1.2M |
| Operating income | −$16.7M | −$16.2M | −$8.8M | −$10.5M | −$9.1M | −$6.5M | −$4.3M | −$3.3M | −$16.6M | −$1.2M |
| EBITDA | −$16.7M | −$16.2M | −$8.8M | −$10.5M | — | — | — | — | — | — |
| Net income | −$13.7M | −$15.6M | −$8.4M | −$10.5M | −$9.1M | −$6.3M | −$4.2M | −$3.2M | −$16.6M | −$1.2M |
| Basic EPSper basic share | -$1.85 | -$4.11 | -$3.04 | -$4.15 | -$3.65 | -$2.90 | -$2.25 | -$1.75 | -$9.45 | — |
| Diluted EPSper diluted share | -$1.85 | -$4.11 | -$3.04 | -$4.15 | -$3.65 | -$2.90 | -$2.25 | -$1.75 | -$9.45 | — |
Owners
Reported shareholders
19.55%of listed shares
Jupiter Topco LLC1.31M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Jupiter Topco LLC | 19.55%1.31M shares |
RA CAPITAL MANAGEMENT, L.P. | 9.94%667.21K shares |
Hendricks Diane | ≈9.85%661.33K shares |
BlackRock, Inc. | 5.20%348.82K shares |
DEERFIELD MANAGEMENT COMPANY, L.P. | 4.82%323.75K shares |
Saturn V Capital Management LP | 4.65%311.98K shares |
Siren, L.L.C. | 4.02%270.12K shares |
ADAR1 Capital Management, LLC | 3.24%217.6K shares |
Polar Capital Holdings Plc | 3.20%214.47K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.12%209.71K shares |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 3.12%209.2K shares |
TCG Crossover Management, LLC | 3.03%203.33K shares |
WELLINGTON MANAGEMENT GROUP LLP | 2.36%158.44K shares |
ORBIMED ADVISORS LLC | 2.35%157.42K shares |
Robinson Chandler | ≈2.28%153.29K shares |
Candriam S.C.A. | 2.14%143.34K shares |
Balyasny Asset Management L.P. | 2.00%134.54K shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.68%112.58K shares |
Alyeska Investment Group, L.P. | 1.49%100K shares |
STATE STREET CORP | 1.38%92.55K shares |
Percentages use 6.71M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Dec 26, 2025Form 4 | Vu Quan AnhChief Financial Officer | BuyCommon Stock | 1.5K | $69.95 | $104.9K | 1.5K |
| Dec 18, 2025Form 4 | KLAUSNER ARTHUR JDirector | SellCommon Stock | 461 | $68.09 | $31.4K | 8.8K |
| Dec 18, 2025Form 4 | KLAUSNER ARTHUR JDirector | SellCommon Stock | 4.7K | $67.06 | $312.5K | 9.2K |
| Sep 24, 2025Form 4 | Tactic Pharma LLC +4Chief Executive Officer | SellCommon Stock | 550.2K | $63.61 | $35.00M | 272.0K |
| Jul 14, 2025Form 4 | Tsuchimoto Kim RDirector | SellCommon Stock | 8.9K | $40.00 | $356.2K | 11.5K |